Tumor Characteristics and Treatment Responsiveness in Pembrolizumab-Treated Non-Small Cell Lung Carcinoma

Area of Science:

• Oncology
• Immunotherapy
• Pathology

Background:

• Pembrolizumab, an immune checkpoint inhibitor (ICI), is a key treatment for non-small cell lung cancer (NSCLC).
• Predicting patient response to pembrolizumab is crucial for personalized therapy.
• Tumor histopathologic features may correlate with treatment outcomes.

Purpose of the Study:

• To investigate the association between pre-treatment histopathologic features and pembrolizumab response in NSCLC patients.
• To identify unique tumor characteristics predictive of favorable outcomes.

Main Methods:

• Retrospective analysis of 84 NSCLC patients treated with pembrolizumab.
• Evaluation of clinical data and pre-treatment histopathologic features.
• Response assessment using Response Evaluation Criteria in Solid Tumors (RECIST).

Main Results:

• Patients with complete or partial response (responsive group) showed significantly higher overall survival.
• Higher pre-treatment viable tumor cell content and tumor-infiltrating lymphocytes (TILs) were observed in responsive groups.
• Lower extracellular stroma proportion was associated with better response.

Conclusions:

• Positive treatment responses to pembrolizumab in NSCLC are linked to better prognosis.
• Viable tumor cell and tumor-infiltrating lymphocyte proportions correlate with treatment responsiveness.
• Further prospective studies are needed to validate these histopathologic predictors.